SG11201802470SA - Egfr kinase inhibitor and preparation method and use thereof - Google Patents
Egfr kinase inhibitor and preparation method and use thereofInfo
- Publication number
- SG11201802470SA SG11201802470SA SG11201802470SA SG11201802470SA SG11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- kinase inhibitor
- egfr kinase
- egfr
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510622837.4A CN106554347B (zh) | 2015-09-25 | 2015-09-25 | Egfr激酶抑制剂及其制备方法和应用 |
| PCT/CN2016/089679 WO2017049992A1 (zh) | 2015-09-25 | 2016-07-11 | Egfr激酶抑制剂及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201802470SA true SG11201802470SA (en) | 2018-04-27 |
Family
ID=58385839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201802470SA SG11201802470SA (en) | 2015-09-25 | 2016-07-11 | Egfr kinase inhibitor and preparation method and use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10710979B2 (zh) |
| EP (1) | EP3354647B1 (zh) |
| JP (1) | JP6752283B2 (zh) |
| KR (1) | KR20180096575A (zh) |
| CN (1) | CN106554347B (zh) |
| AU (1) | AU2016327857B2 (zh) |
| BR (1) | BR112018005795A2 (zh) |
| CA (1) | CA2999785C (zh) |
| RU (1) | RU2018115278A (zh) |
| SG (1) | SG11201802470SA (zh) |
| WO (1) | WO2017049992A1 (zh) |
| ZA (1) | ZA201802141B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI778943B (zh) | 2015-10-01 | 2022-10-01 | 美商潛能醫療有限公司 | 抗tigit抗原結合蛋白及其使用方法 |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110025224A (ko) * | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI545115B (zh) | 2010-11-01 | 2016-08-11 | 阿維拉製藥公司 | 雜環化合物及其用途 |
| JP5957003B2 (ja) * | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | 変異体選択的ｅｇｆｒ阻害剤およびその使用 |
| CN104583195B (zh) * | 2012-09-12 | 2018-08-17 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| NO2718543T3 (zh) * | 2014-02-04 | 2018-01-06 | ||
| CN104860890B (zh) * | 2015-04-29 | 2018-03-13 | 上海泓博智源医药股份有限公司 | T790m突变型egfr的抑制剂及其在制备抗肿瘤药物中的应用 |
| CN105461640B (zh) | 2015-12-02 | 2017-11-21 | 芷威（上海）化学科技有限公司 | 一种酪氨酸激酶抑制剂的制备方法 |
-
2015
- 2015-09-25 CN CN201510622837.4A patent/CN106554347B/zh active Active
-
2016
- 2016-07-11 JP JP2018535217A patent/JP6752283B2/ja not_active Expired - Fee Related
- 2016-07-11 US US15/763,156 patent/US10710979B2/en active Active
- 2016-07-11 KR KR1020187011753A patent/KR20180096575A/ko not_active Application Discontinuation
- 2016-07-11 BR BR112018005795A patent/BR112018005795A2/pt not_active Application Discontinuation
- 2016-07-11 RU RU2018115278A patent/RU2018115278A/ru not_active Application Discontinuation
- 2016-07-11 WO PCT/CN2016/089679 patent/WO2017049992A1/zh active Application Filing
- 2016-07-11 SG SG11201802470SA patent/SG11201802470SA/en unknown
- 2016-07-11 CA CA2999785A patent/CA2999785C/en active Active
- 2016-07-11 AU AU2016327857A patent/AU2016327857B2/en not_active Ceased
- 2016-07-11 EP EP16847874.1A patent/EP3354647B1/en active Active
-
2018
- 2018-04-03 ZA ZA2018/02141A patent/ZA201802141B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106554347A (zh) | 2017-04-05 |
| CA2999785A1 (en) | 2017-03-30 |
| EP3354647B1 (en) | 2022-08-24 |
| JP6752283B2 (ja) | 2020-09-09 |
| WO2017049992A1 (zh) | 2017-03-30 |
| JP2018536698A (ja) | 2018-12-13 |
| AU2016327857B2 (en) | 2019-10-03 |
| US20180346444A1 (en) | 2018-12-06 |
| CA2999785C (en) | 2020-10-27 |
| RU2018115278A3 (zh) | 2019-10-28 |
| US10710979B2 (en) | 2020-07-14 |
| RU2018115278A (ru) | 2019-10-28 |
| BR112018005795A2 (pt) | 2019-01-15 |
| EP3354647A4 (en) | 2019-04-03 |
| KR20180096575A (ko) | 2018-08-29 |
| CN106554347B (zh) | 2020-10-30 |
| AU2016327857A1 (en) | 2018-04-26 |
| ZA201802141B (en) | 2019-01-30 |
| EP3354647A1 (en) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279258B (en) | tyrosine kinase inhibitors | |
| HK1252693A1 (zh) | Egfr抑制劑及其使用方法 | |
| HK1248231A1 (zh) | 取代的喹唑啉化合物和其使用方法 | |
| ZA201701465B (en) | Egfr inhibitor, and preparation and application thereof | |
| HK1246286A1 (zh) | Lrrk2抑制劑及其製備和使用方法 | |
| IL259711A (en) | Methods for the preparation of protein kinase inhibitors and their medical use | |
| PL3277681T3 (pl) | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm | |
| HK1249497A1 (zh) | Ebna1抑制劑及其使用方法 | |
| ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| GB201514760D0 (en) | Compounds and method of use | |
| ZA201802141B (en) | Egfr kinase inhibitor and preparation method and use thereof | |
| HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
| HK1250926A1 (zh) | 抑制劑及其應用 | |
| ZA201903845B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| GB201502247D0 (en) | Formulation and method |